Skip to content

Research at St Andrews

The implications of model–informed drug discovery and development for tuberculosis

Research output: Contribution to journalArticle

Author(s)

Morris Muliaditan, Geraint R. Davies, Ulrika S. H. Simonsson, Stephen H. Gillespie, Oscar Della Pasqua

School/Research organisations

Abstract

Despite promising advances in the field and highly effective first-line treatment, an estimated 9.6 million people are still infected with tuberculosis (TB). Innovative methods are required to effectively transition the growing number of compounds into novel combination regimens. However, progression of compounds into patients occurs despite the lack of clear understanding of the pharmacokinetic-pharmacodynamic (PK/PD) relations. The PreDiCT-TB consortium was established in response to the existing gaps in TB drug development. The aim of the consortium is to develop new preclinical tools in concert with an in silico model-based approach, grounded in PKPD principles. Here, we highlight the potential impact of such an integrated framework on various stages in TB drug development and on the dose rationale for drug combinations.
Close

Details

Original languageEnglish
Pages (from-to)481-486
Number of pages6
JournalDrug Discovery Today
Volume22
Issue number3
Early online date28 Sep 2016
DOIs
Publication statusPublished - Mar 2017

    Research areas

  • PKPD, Tuberculosis, Drug development , Modelling and simulation

Discover related content
Find related publications, people, projects and more using interactive charts.

View graph of relations

Related by author

  1. Mimicking in-vivo exposures to drug combinations in-vitro: anti-tuberculosis drugs in lung lesions and the hollow fiber model of infection

    Kloprogge, F., Hammond, R., Kipper, K., Gillespie, S. H. & Della Pasqua, O., 13 Sep 2019, In : Scientific Reports. 9, 8 p., 13228.

    Research output: Contribution to journalArticle

  2. A tuberculosis molecular bacterial load assay (TB-MBLA)

    Sabiiti, W., Mtafya, B. A., Alferes De Lima, D., Dombay, E., Baron, V. O., Azam, K., Orascova, K., Sloan, D. J. & Gillespie, S. H., 6 Sep 2019, (Accepted/In press) In : Journal of Visualized Experiments.

    Research output: Contribution to journalArticle

  3. Can phenotypic data complement our understanding of antimycobacterial effects for drug combinations?

    Kloprogge, F., Hammond, R., Copas, A., Gillespie, S. H. & Della Pasqua, O., 25 Aug 2019, In : Journal of Antimicrobial Chemotherapy. Advance article, 7 p.

    Research output: Contribution to journalArticle

  4. Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV status

    Tweed, C. D., Crook, A. M., Dawson, R., Diacon, A. H., McHugh, T. D., Mendel, C. M., Meredith, S. K., Mohapi, L., Murphy, M. E., Nunn, A. J., Phillips, P. P. J., Singh, K. P., Spigelman, M. & Gillespie, S. H., 14 Aug 2019, In : BMC Pulmonary Medicine. 19, 9 p., 152.

    Research output: Contribution to journalArticle

  5. Model-based relationship between the molecular bacterial load assay and time-to-positivity in liquid culture

    Svensson, R. J., Sabiiti, W., Kibiki, G. S., Ntinginya, N. E., Bhatt, N., Davies, G., Gillespie, S. H. & Simonsson, U. S. H., 29 Jul 2019, In : Antimicrobial Agents and Chemotherapy. Early

    Research output: Contribution to journalArticle

Related by journal

  1. The extent and effects of patient involvement in pictogram design for written drug information: a short systematic review

    van Beusekom, M. M., Kerkhoven, A. H., Bos, M. J. W., Guchelaar, H-J. & van den Broek, J. M., Jun 2018, In : Drug Discovery Today. 23, 6, p. 1312-1318 7 p.

    Research output: Contribution to journalReview article

  2. Recent progress in antiretrovirals - lessons from resistance

    Adamson, C. S. & Freed, E. O., May 2008, In : Drug Discovery Today. 13, 9-10, p. 424-432

    Research output: Contribution to journalArticle

ID: 246364035

Top